Are Capillary Technologies India Ltd latest results good or bad?

1 hour ago
share
Share Via
Capillary Technologies India Ltd's latest Q4 FY26 results show strong growth, with a net profit of ₹43.36 crores and revenue of ₹191.35 crores, indicating improved operational performance. However, concerns about the sustainability of earnings due to reliance on non-operating income suggest caution moving forward.
Capillary Technologies India Ltd's latest financial results for Q4 FY26 indicate a notable operational performance, with significant growth in both net profit and revenue. The company reported a net profit of ₹43.36 crores, reflecting a substantial increase compared to the previous quarter and the same quarter last year. Revenue for the quarter reached ₹191.35 crores, marking a steady quarter-on-quarter growth of 3.97% and a year-on-year increase of 20.35%.
The operating margin, excluding other income, improved to 16.41%, up by 283 basis points from the previous quarter, suggesting enhanced operational efficiency as the company scales. However, it is important to note that a considerable portion of the profit was bolstered by other income, which accounted for over half of the profit before tax, raising questions about the sustainability of these earnings. In terms of overall financial health, Capillary Technologies maintains a robust balance sheet, with minimal debt and a strong cash position. Despite these positive indicators, the company has seen an adjustment in its evaluation, reflecting the complexities of its financial performance, particularly regarding the quality of earnings and historical growth metrics. The data from the previous quarter (Q3 FY26) also shows a significant turnaround, with net profit jumping from near breakeven levels to the current figures. This suggests that while the company is experiencing a positive trend in operational performance, there are underlying concerns regarding the reliance on non-operating income and the sustainability of growth moving forward. Overall, Capillary Technologies appears to be at a critical juncture, with recent results indicating operational improvements, yet the reliance on non-core income and historical growth stagnation warrant careful monitoring in the upcoming quarters.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News